How Much Longer Will We Put Up With $100,000 Cancer Drugs?
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Critical parameters in targeted drug development: the pharmacological audit trailSeminars in Oncology, 2016
- USA grapples with high drug costsThe Lancet, 2015
- Five Years of Cancer Drug ApprovalsJAMA Oncology, 2015
- The $2.6 Billion Pill — Methodologic and Policy ConsiderationsNew England Journal of Medicine, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Academic drug discovery centres: the economic and organisational sustainability of an emerging modelDrug Discovery Today, 2014
- Market spiral pricing of cancer drugsCancer, 2013
- Discovery of small molecule cancer drugs: Successes, challenges and opportunitiesMolecular Oncology, 2012
- US academic drug discoveryNature Reviews Drug Discovery, 2011
- Risks in new drug development: Approval success rates for investigational drugsClinical Pharmacology & Therapeutics, 2001